Jul 2022 $4 M No. 4 $2 to $10 million 16
Arch Therapeutics, Inc.: Raise no. 4, Jul 2022 × Investors in this round 16 investors had bought by the notice of Jul 19, 2022: 16 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $240,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Nevada People named in the notice Daniel M. Yrigoyen · Executive Officer Michael S. Abrams · Executive Officer Terrence W. Norchi · Executive Officer, Director Guy W. Fish · Director Laurence W. Hicks · Director Punit W. Dhillon · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Maxim Group LLP (CRD 120708) · New York, New York Sold in all US states Remarks in the notice On fees: “Some of the proceeds may be used for general working capital purposes including the payment of salaries and other fees to those listed in Item 3. Additionally, warrants were issued to the placement agent at an exercise price of $0.0503 per share.”Signed by Michael S. Abrams, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 19, 2022. Read the notice at the SEC .
equity, options SEC Feb 2021 $7 M No. 3 $2 to $10 million 9
Arch Therapeutics, Inc.: Raise no. 3, Feb 2021 × Investors in this round 9 investors had bought by the notice of Feb 25, 2021: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $7 M of $8 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $492,750
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Nevada People named in the notice Richard E. Davis · Executive Officer Terrence W. Norchi · Executive Officer, Director James R. Sulat · Director Punit W. Dhillon · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co. (CRD 375) · New York, New York Sold in all US states Remarks in the notice On fees: “Excludes value of warrants to purchase up to 3,234,375 shares at an exercise price of $0.20 per share”On the use of proceeds: “Some of the proceeds may be used for general working capital purposes including the payment of salaries and other fees to those listed in Item 3.”Signed by Terrence Norchi, President, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 25, 2021. Read the notice at the SEC .
equity, options SEC May 2016 $3 M No. 2 $2 to $10 million 18
Arch Therapeutics, Inc.: Raise no. 2, May 2016 × Investors in this round 18 investors had bought by the notice of Jun 2, 2016: 18 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $4 M offered; $0 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $170,960
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Nevada People named in the notice Richard E. Davis · Executive Officer Terrence W. Norchi · Executive Officer, Director Avtar W. Dhillon · Director James R. Sulat · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round MAXIM GROUP LLC (CRD 120708) · New York, New York Sold in all US states Remarks in the notice On the use of proceeds: “Some of the proceeds may be used for general working capital purposes including the payment of salaries and other fees to those listed in Item 3.”Signed by Terrence Norchi, President, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 2, 2016. Read the notice at the SEC .
equity, options SEC Feb 2014 $3 M No. 1 $2 to $10 million 9
Arch Therapeutics, Inc.: Raise no. 1, Feb 2014 × Investors in this round 9 investors had bought by the notice of Feb 7, 2014: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Nevada People named in the notice Alan Barber · Executive Officer Norchi Terrence · Executive Officer, Director William Cotter · Executive Officer Arthur Rosenthal · Director Avtar Dhillon · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Terrence Norchi, President, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 7, 2014. Read the notice at the SEC .
equity, options SEC Jun 2013 $7 M Issued in a merger or acquisition $2 to $10 million 58
Arch Therapeutics, Inc.: Private sale, Jun 2013 × Investors in this round 58 investors had bought by the notice of Jul 8, 2013: 52 accredited, 6 not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $7 M of $7 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice Alan W Barber · Executive Officer Terrence W Norchi · Executive Officer, Director Arthur W Rosenthal · Director Avtar W Dhillon · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Calculated based on a per share price of $0.50, which is the price paid for the Issuer's common stock by an investor in a recent separate private placement and was used due to the limited trading market for the Issuer's common stock.”On a merger: “Shares of common stock issued in exchange for the cancellation of equity or rights to acquire equity of Arch Biosurgery, Inc. upon the closing of a reverse merger with such entity.”Signed by Terrence W. Norchi, President, chief executive officer. Source: SEC Form D, newest notice filed Jul 8, 2013. Read the notice at the SEC .
equity SEC